News

Under the terms of the deal, the CUE Biologics platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets for the treatment of

IONIS-JBI2-2.5Rx is designed to locally reduce the production of an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease. Jansen will now

Hemlibra is a bispecific factor IXa- and factor X-directed antibody. The therapy which has been approved for both adults and children, functions by bridging other factors in the blood

The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and Sanofi Ventures. “Our mission is to develop potentially disease-modifying therapies

The multi-year strategic license agreement, initiated in October 2015, will encompass additional disease targets and expand the collaboration. Under the revised terms of the agreement, Arvinas is eligible

MPS VII is a progressive and debilitating inherited, rare genetic disease which previously didn’t have any approved therapy. It is a metabolic lysosomal storage disorder (LSD) resulting from

Fasenra has been approved as an add-on maintenance treatment for patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. The approval was based

Through these investments, executed over a multi-year period and capped recently in 2017, Purdue is establishing a portfolio of drug candidates with the potential to deliver new cancer

The American company had announced its plan to sell the business in July as it was anticipating that the upcoming drug distribution reform in China will affect its